药物性血栓预防与临床相关出血及医院获得性贫血在内科住院患者中的关联:内科患者医院获得性静脉血栓栓塞风险分层研究
在3家瑞士大学医院的前瞻性队列中,1305例内科住院患者里809例(62%)接受药物性血栓预防(pTPX)。pTPX与临床相关出血(CRB)无显著关联,但与医院获得性贫血(HAA)存在关联(校正比值比1.4,95%CI 1.0-2.1)。作者认为需遵循指南对静脉血栓栓塞风险增高且出血风险低的内科住院患者使用pTPX。
要点
- pTPX与临床相关出血无显著关联,支持低出血风险内科住院患者中的安全性。
- 医院获得性贫血发生率为20.2%,pTPX组23.2% vs 无pTPX组15.3%。
- pTPX与医院获得性贫血存在关联,校正比值比1.4(95%CI 1.0-2.1)。
核心结论
- 研究确认pTPX在出血风险低的内科住院患者中是安全的,但发现pTPX与医院获得性贫血存在关联。
研究设计与样本
- 前瞻性队列研究,在3家瑞士大学医院开展,纳入入住内科病房且未接受治疗性抗凝的成年患者,共1305例,平均年龄63.7岁,44%为女性,90%为低出血风险。
主要发现
- 809例(62%)接受pTPX;临床相关出血发生率为2.4/1000患者日,pTPX组与无pTPX组无显著差异,pTPX与临床相关出血无显著关联。
- 医院获得性贫血发生率为20.2%,pTPX组23.2% vs 无pTPX组15.3%;医院获得性贫血发生率为21.2/1000患者日,pTPX组与无pTPX组无显著差异。
- 校正感染、住院时长和国际内科静脉血栓栓塞预防登记出血风险评分后,pTPX与医院获得性贫血存在关联(校正比值比1.4;95%CI 1.0-2.1)。
临床怎么用
- 作者认为,需遵循指南对静脉血栓栓塞风险增高且出血风险低的内科住院患者使用pTPX。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pharmacologic thromboprophylaxis (pTPX) might exacerbate the risk of clinically relevant bleeding (CRB) and hospital-acquired anemia (HAA) in older multimorbid inpatients. OBJECTIVES: We aimed to evaluate the association of pTPX use with CRB and HAA. METHODS: We used data from a prospective cohort study conducted in 3 Swiss university hospitals. Adult patients admitted to internal medicine wards with no therapeutic anticoagulation were included. pTPX use was ascertained during hospitalization. Outcomes were in-hospital CRB and HAA. We calculated incidence rates by status of pTPX. We assessed the association of pTPX with CRB using survival analysis and with HAA using logistic regression, adjusted for infection, length of stay, and the International Medical Prevention Registry on Venous Thromboembolism bleeding risk score. RESULTS: Among 1305 patients (mean age, 63.7 years; 44% women, 90% at low risk of bleeding), 809 (62%) received pTPX. The incidence of CRB was 2.4 per 1000 patient-days and was not significantly higher in patients with pTPX than in those without. We found no significant association between pTPX and CRB. HAA was frequent (20.2%) and higher in patients with pTPX than in those without (23.2% vs 15.3%). The incidence of HAA was 21.2 per 1000 patient-days and did not significantly differ between patients with pTPX and those without. We found an association between pTPX and HAA (adjusted odds ratio, 1.4; 95% CI, 1.0-2.1). CONCLUSION: Our study confirmed the safety of pTPX in medical inpatients at low risk of bleeding but identified an association between pTPX and HAA. Adherence to guidelines that recommend administering pTPX to medical inpatients at increased venous thromboembolism risk and low bleeding risk is necessary.
引用
- Choffat D, Rossel JB, Aujesky D, et al. Association of pharmacologic thromboprophylaxis with clinically relevant bleeding and hospital-acquired anemia in medical inpatients: the risk stratification for hospital-acquired venous thromboembolism in medical patients study. J Thromb Haemost. 2023. PMID: 38072378. doi:10.1016/j.jtha.2023.11.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。